Proactive - Interviews for investors
BioVie advances long COVID trial, top-line data expected by summer
BioVie is advancing a clinical trial for long COVID, focusing on central nervous system symptoms. The company received a $13 million grant for this research. Top-line data from the trial is expected by the end of summer.